Valuation Abbott Laboratories CBOE
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time
CBOE
23:30:00 08/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 91.46 EUR | -2.83% |
|
-3.36% | -14.17% |
| 09-08 | Abbott Receives FDA Approval for Device to Treat Abnormal Heart Rhythm | DJ |
| 09-08 | Abbott Receives FDA Approval for TactiFlex Duo Ablation Catheter to Treat Abnormal Heart Rhythms | CI |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 182,590 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -16.19% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 206,529 | 203,547 | 199,857 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -7.08% | -1.44% | -1.81% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 30.3x | 23.3x | 20.8x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.81x | 3.65x | 3.46x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -4.82x | 0.8x | 1.7x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.63x | 3.34x | 3.13x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.11x | 3.72x | 3.42x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.8x | 13.9x | 12.5x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.6x | 15.6x | 14x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26x | 21.8x | 19.6x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.84% | 4.6% | 5.11% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.44% | 2.6% | 2.74% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.486 | 4.524 | 5.074 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.6% | 57.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,304 | 54,647 | 58,409 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,090 | 14,598 | 16,020 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,319 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,232 | 7,924 | 8,850 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 105.52 | 105.52 | 105.52 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/1/22 | 25/1/23 | 24/1/24 | 22/1/25 | 22/1/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.27x | 4.11x | 15.78x | 2.44% | 183B | |
| 19.54x | 3.57x | 12.75x | 3.07% | 118B | |
| 17.78x | 0.21x | 12.97x | 0.74% | 61.96B | |
| 28.6x | 7.04x | 18.13x | 1.4% | 50.6B | |
| 34.51x | 3.35x | 11.49x | 2.19% | 48.78B | |
| 33.88x | 5.95x | 18.69x | -.--% | 31.9B | |
| 44.79x | 1.3x | 12.02x | 0.21% | 30.44B | |
| 39.39x | 6.89x | 24.74x | 0.27% | 23.77B | |
| 17.34x | 2.76x | 9.79x | 1.6% | 22.26B | |
| Average | 29.57x | 3.91x | 15.15x | 1.32% | 63.39B | |
| Weighted average by Cap. | 27.76x | 3.78x | 14.79x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
